Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: Regulation by the von Hippel-Lindau gene and hypoxia

Cancer Research

Volumn 61, Issue 7, 2001, Pages 3206-3211

  Gunningham, Sarah P ^a   Currie, Margaret J ^a   Han, Cheng ^b   Turner, Kevin ^b   Scott, Prudence A E ^a   Robinson, Bridget A ^a   Harris, Adrian L ^b   Fox, Stephen B ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN B; VASCULOTROPIN C;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER INVASION; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; KIDNEY CARCINOMA; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VON HIPPEL LINDAU DISEASE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CELL HYPOXIA; ENDOTHELIAL GROWTH FACTORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; KIDNEY; KIDNEY NEOPLASMS; LIGASES; MALE; MIDDLE AGED; PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0035300599     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
2. Vascular endothelial growth factor expression is increased in renal cell carcinoma
3. Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma
4. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma
5. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma
6. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
7. Vascular endothelial growth factor platelet counts and prognosis in renal cancer
8. Renal cell carcinoma: Relevance of angiogenetic factors
9. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
10. Cloning and characterization of a novel human gene related to vascular endothelial growth factor
11. Vascular endothelial growth factor B, a novel growth factor for endothelial cells
12. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinase
13. Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4
14. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells
15. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia
16. Proteolytic processing regulates receptor specificity and activity of VEGF-C
17. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
18. Vascular endothelial growth factors VEGF-B and VEGF-C
19. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development
20. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
21. Prognostic significance of morphologic parameters in renal cell carcinoma
22. Tumor suppression by the human von Hippel-Lindau gene product
23. Von Hippel-Lindau syndrome: Target for antivascular endothelial growth factor (VEGF) receptor therapy
24. The short form of the alternatively spliced flt-4 but not its ligand VEGF-C is related to lymph node metastasis in human breast cancers
25. A reliable external control for ribonuclease protection assays
26. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR
27. Identification of a human VPF/VEGF 3′ untranslated region mediating hypoxia-induced mRNA stability
28. Renal microvascular assembly and repair: Power and promise of molecular definition
29. Direct visualization of renal vascular morphogenesis in Flk1 heterozygous mutant mice
30. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?
31. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer
32. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis
33. VEGF, VEGF-B, VEGF-C, and their receptors, K. D. R., FLT-1, and FLT-4 during the neoplastic progression of human colonic mucosa
34. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma
35. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity
36. Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor
37. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene
38. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
39. VHL takes HIF's breath away
40. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms
41. Comparison of VEGF, VEGF-B, VEGF-C, and Ang-1 mRNA regulation by serum, growth factors, oncoproteins, and hypoxia
42. Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: Molecular evidence for "placental hyperoxia" in intrauterine growth restriction
43. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells
44. Analysis of the promoter region of the human VEGF-related factor gene
45. Genomic organization of human and mouse genes for vascular endothelial growth factor C
46. VEGF-B expression in human breast cancers is associated with positive lymph node status